BioSpace News Archive

Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quarter and full year of 2023 as well as an update to the business.

Inspira™ Technologies OXY B.H.N. Ltd., a breakthrough medical technology company, has announced that the Company is progressing towards 510 clearance from the U.S. Food & Drug Administration for its INSPIRA™ ART100 in the first half of 2024.

Alzheon, Inc. announced its participation in the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal from March 5–9, 2024.

Nuvalent, Inc. announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to NVL-520 for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer who have been previously treated with two or more ROS1 tyrosine kinase inhibitors.

SpringWorks Therapeutics, Inc. reported financial results for the fourth quarter and full year periods ended December 31, 2023 and provided an update on recent company developments.

KalVista Pharmaceuticals, Inc. announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting that took place in Washington, DC.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET.

BD, a leading global medical technology company, announced that Dave Hickey has informed the company of his intent to retire from BD, effective July 1.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.